MENU
BIB
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

BIB stock forecast, quote, news & analysis

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®... Show more

Category: #Trading
BIB
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for BIB with price predictions
Oct 01, 2026

BIB in +1.27% Uptrend, growing for three consecutive days on September 29, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BIB advanced for three days, in 290 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

BIB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 208 of 221 cases where BIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The 10-day RSI Indicator for BIB moved out of overbought territory on August 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 24 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 56 of 63 cases where BIB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BIB as a result. In 80 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for BIB turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 46 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

BIB moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Illumina (NASDAQ:ILMN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Guardant Health (NASDAQ:GH), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®. The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.

Market Cap

The average market capitalization across the ProShares Ultra Nasdaq Biotechnology (BIB) ETF is 8.63B. The market cap for tickers in the group ranges from 70.46M to 226.05B. AMGN holds the highest valuation in this group at 226.05B. The lowest valued company is GOSS at 70.46M.

High and low price notable news

The average weekly price growth across all stocks in the ProShares Ultra Nasdaq Biotechnology (BIB) ETF was 192%. For the same ETF, the average monthly price growth was 152%, and the average quarterly price growth was 319%. KOD experienced the highest price growth at 196%, while QURE experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the ProShares Ultra Nasdaq Biotechnology (BIB) ETF was 12%. For the same stocks of the ETF, the average monthly volume growth was 41% and the average quarterly volume growth was -13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 69
Price Growth Rating: 54
SMR Rating: 86
Profit Risk Rating: 83
Seasonality Score: 12 (-100 ... +100)
View a ticker or compare two or three
BIB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Trading

Category
Trading--Leveraged Equity
Address
ProShares Trust7501 Wisconsin Avenue,Suite 1000Bethesda
Phone
N/A
Web
www.proshares.com
BIB in +1.27% Uptrend, growing for three consecutive days on September 29, 2026